Redefining how we build better disease maps, follows the theme “Building Better Models of Diseases Together”, the Congress has been organized to discuss redefining tools needed, how we share and our roles as researchers citizens and funders. It will provide participants with an understanding of current efforts to build better maps of disease together. The last session entitled “Next Steps” is a workshop where participants will gather in subgroups to focus on the projects and components and to ask what opportunities are worth resourcing to promote sustainability."
Bio
Stephen Friend
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
John Wilbanks
As VP of Science, John Wilbanks runs the Science Commons project at Creative Commons. He came to Creative Commons from a Fellowship at the World Wide Web Consortium in Semantic Web for Life Sciences. Previously, he founded and led to acquisition Incellico, a bioinformatics company that built semantic graph networks for use in pharmaceutical research & development. Previously, John was the first Assistant Director at the Berkman Center for Internet and Society at Harvard Law School and also worked in US politics as a legislative aide to U.S. Representative Fortney (Pete) Stark.
John holds a Bachelor of Arts in Philosophy from Tulane University and studied modern letters at the Universite de Paris IV (La Sorbonne). He was a research affiliate at the MIT Computer Science and Artificial Intelligence Laboratory in the project on Mathematics and Computation. John also serves on the Advisory Boards of the U.S. National Library of Medicine’s PubMed Central, the Open Knowledge Foundation, the Open Knowledge Definition, and the International Advisory Board of the Prix Ars Electronica’s Digital Communities awards. He also serves on the Board of Directors of the Fedora Commons digital repository organization.
Director of Sage Bionetworks John Wilbanks examines the epistemology of science funding. Wilbanks explains most science funding goes into 'known knowns' because of the fear of undesired outcomes.
Application of engineering principles and equipment to biology and medicine. It includes the development and fabrication of life-support systems for underwater and space exploration, devices for medical treatment (seedialysis, prosthesis), and instruments for monitoring biological processes. Development has been particularly rapid in the area of artificial organs, which culminated in the implantation of an artificial heart into a human being in 1982. Bioengineers also develop equipment that enables humans to maintain body functions in hostile environments, such as the space suits worn by astronauts during extravehicular maneuvers.